Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,019.43 -52.20 (-1.03%) Dow
37,911.73 -549.19 (-1.43%) Nasdaq
15,486.02 -226.73 (-1.44%) Bitcoin USD
64,211.66 -518.05 (-0.80%) CMC Crypto 200
1,381.99 -0.59 (-0.04%)
Altimmune, Inc. (ALT)
| Previous close | 7.08 |
| Open | 6.88 |
| Bid | 6.94 x 1100 |
| Ask | 7.01 x 400 |
| Day's range | 6.78 - 7.25 |
| 52-week range | 2.09 - 14.84 |
| Volume | |
| Avg. volume | 4,690,848 |
| Market cap | 496.267M |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.66 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 Jan 2017 |
| 1y target est | 21.13 |
GlobeNewswireAltimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results showed a direct anti-fibrotic effect of pemvidutide in anon-steatotic model of liver fibrosis Cash, cash equivalents and short-term investments of $198.0 million at December 31, 2023 Webcast to be held to
- GlobeNewswire
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations we
- GlobeNewswire
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease1 will be presented at the NASH-TAG Conference, which will be held in Park City, UT on January 4-6, 2024. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH2. Det
